首页|GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
国家科技期刊平台
NETL
NSTL
万方数据
Atrial fibrillation(AF)is the most common cardiac arrhythmia.Many medical conditions,including hypertension,diabetes,obesity,sleep apnea,and heart failure(HF),increase the risk for AF.Car-diomyocytes have unique metabolic characteristics to maintain adenosine triphosphate production.Significant changes occur in myocardial metabolism in AF.Glucagon-like peptide-1 receptor agonists(GLP-1 RAs)have been used to control blood glucose fluctuations and weight in the treatment of type 2 diabetes mellitus(T2DM)and obesity.GLP-1 RAs have also been shown to reduce oxidative stress,inflammation,autonomic nervous system modulation,and mitochondrial function.This article reviews the changes in metabolic characteristics in cardiomyocytes in AF.Although the clinical trial outcomes are unsatisfactory,the findings demonstrate that GLP-1 RAs can improve myocardial metabolism in the presence of various risk factors,lowering the incidence of AF.
Department of Cardiovascular Medicine,Second Xiangya Hospital,Central South University,Changsha,410011,China
Xiangya School of Medicine,Central South University,Changsha,410008,China
Center for Precision Medicine and Division of Cardiovascular Medicine,Department of Medicine,School of Medicine,University of Missouri,Columbia,MO,65211,USA
Clinical Medical Technology Innovation Project of Hunan Science and Technology Agency,China
国家科技期刊平台
NSTL
万方数据
